Medgenics

Medgenics Granted Patent for Sustained Delivery of Anemia Treatment

The Biopump is intended to provide safe, sustained delivery of erythropoietin for anemia patients.

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics’ EPODURE Biopump technology for delivery of erythropoietin (EPO). Medgenics is developing EPODURE to address the need for safer, sustained treatment of anemia.

No votes yet
Syndicate content